Examining Hyperhidrosis (Excessive Sweating): A Managed Markets Update on New Treatments, Featuring a Patient Perspective

https://www.pharmacytimes.org/on-demand/examining-hyperhidrosis-excessive-sweating-a-managed-markets-update-on-new-treatments-featuring-a-patient-perspective

Related Videos

Related Content

Advertisement

October 7th 2024

Lung Cancer Experts Encourage Use of System-Based Interventions to Address Racial Disparities

Brooke McCormick

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, recommending system-based interventions to improve care equity for patients of color.

October 3rd 2024

Dr Rick Chapman Discusses Key Insights From the Center’s Rare Disease Project

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.

October 7th 2024

CRC Screening Increases in Patients Aged 45 to 49 After USPSTF Recommendation

Julia Bonavitacola

The updated guidelines from the US Preventive Services Task Force (USPSTF) have led to an increase in screening for colorectal cancer (CRC) in individuals aged 45 to 49 years.

September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

Maggie L. Shaw

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

October 7th 2024

Experts Highlight AI's Potential to Enhance ILD Diagnostic Accuracy Amid Limitations

Brooke McCormick

Experts at the CHEST 2024 annual meeting agreed that artificial intelligence (AI) should not be relied upon entirely, but instead be used as a tool by radiologists to make a diagnosis of interstitial lung disease (ILD).

October 7th 2024

Substantial Delays in Postapproval Pediatric Testing for New Drugs

Hayden E. Klein

Less than a third of FDA-mandated trials for drugs approved between 2015 and 2021 had been completed by May 2024.

Related Content

Advertisement

October 7th 2024

Lung Cancer Experts Encourage Use of System-Based Interventions to Address Racial Disparities

Brooke McCormick

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, recommending system-based interventions to improve care equity for patients of color.

October 3rd 2024

Dr Rick Chapman Discusses Key Insights From the Center’s Rare Disease Project

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.

October 7th 2024

CRC Screening Increases in Patients Aged 45 to 49 After USPSTF Recommendation

Julia Bonavitacola

The updated guidelines from the US Preventive Services Task Force (USPSTF) have led to an increase in screening for colorectal cancer (CRC) in individuals aged 45 to 49 years.

September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

Maggie L. Shaw

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.

October 7th 2024

Experts Highlight AI's Potential to Enhance ILD Diagnostic Accuracy Amid Limitations

Brooke McCormick

Experts at the CHEST 2024 annual meeting agreed that artificial intelligence (AI) should not be relied upon entirely, but instead be used as a tool by radiologists to make a diagnosis of interstitial lung disease (ILD).

October 7th 2024

Substantial Delays in Postapproval Pediatric Testing for New Drugs

Hayden E. Klein

Less than a third of FDA-mandated trials for drugs approved between 2015 and 2021 had been completed by May 2024.